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Objectives
To report outcomes from a multiparametric (mp) magnetic
resonance imaging (MRI)-based active surveillance
programme that did not include performing protocol biopsies
after the first confirmatory biopsy.
Patients and Methods
All patients diagnosed with Gleason 3 + 3 prostate cancer
because of a raised PSA level who underwent mpMRI after
diagnosis were included. Patients were recorded in a
prospective clinical database and followed up with PSA
monitoring and repeat MRI. In patients who remained on
active surveillance after the first MRI (with or without
confirmatory biopsy), we investigated PSA dynamics for
association with subsequent progression. Comparison between
first and second MRI scans was undertaken. Outcomes
assessed were: progression to radical therapy at first MRI/
confirmatory biopsy and progression to radical therapy in
those who remained on active surveillance after first MRI.
Results
A total of 211 patients were included, with a median of
4.2 years of follow-up. The rate of progression to radical
therapy was significantly greater at all stages among
patients with visible lesions than in those with initially
negative MRI (47/125 (37.6%) vs 11/86 (12.8%); odds ratio
4.1 (95% CI 2.0–8.5), P < 0.001). Only 1/56 patients
(1.8%) with negative initial MRI scans who underwent a
confirmatory systematic biopsy had upgrading to Gleason 3
+ 4 disease. PSA velocity was significantly associated with
subsequent progression in patients with negative initial MRI
(area under the curve 0.85 [95% CI 0.75–0.94]; P <0.001).
Patients with high-risk visible lesions on first MRI who
remained on active surveillance had a high risk of
subsequent progression 19/76 (25.0%) vs 9/84 (10.7%) for
patients with no visible lesions, despite reassuring targeted
and systematic confirmatory biopsies and regardless of PSA
dynamics.
Conclusion
Men with low-risk Gleason 3 + 3 prostate cancer on active
surveillance can forgo protocol biopsies in favour of MRI and
PSA monitoring with selective re-biopsy.
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Introduction
It is now accepted that active surveillance is the first-line
treatment option for men with low-risk prostate cancer
[1,2].
Most active surveillance programmes involve repeat ‘protocol’
or ‘confirmatory’ prostate biopsy. This is performed 1 year
after diagnosis and at varying time points subsequently. The
reason for this is that, historically, up to 35% of cases were
upgraded [3].
In 2014, the National Institute for Health and Care
Excellence (NICE) recommended multiparametric MRI
(mpMRI) scanning at the time of diagnosis for men on active
surveillance in the UK [4]. Other aspects of active
surveillance (such as the confirmatory biopsy) were not
changed. It is now recognized that MRI targeted biopsy in
addition to systematic biopsy improves detection of
upgrading [5–7]. There is early evidence that using MRI with
or without a PSA adjunct to risk-stratify men for
confirmatory biopsy may allow safe omission of confirmatory
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biopsy. However, these studies lack long-term follow-up to
confirm safety [8–11]. Prostate biopsy in men on active
surveillance is a painful procedure that contributes to reduced
active surveillance compliance [12]. It is also a morbid and
costly procedure [13].
There is limited evidence about the use of serial MRI scans
for monitoring in active surveillance. Four small studies with
short follow-up have been published reporting serial MRI
findings [14–17] in men on active surveillance. One recent
study, included 124 men with Gleason 3 + 3 cancer [18].
That study demonstrated low rates of progression over three
years; however, the role of the early confirmatory biopsy was
not assessed, the surveillance protocol involved ongoing
‘protocoled’ biopsies and there were only 23 cases of
progression. Larger studies with longer follow-up, not
performing ongoing protocol biopsies, are needed. In
addition, many studies using MRI in prostate cancer
diagnosis are based on trials, or are conducted at world
expert centres. These studies use 3-Tesla MRI, expensive
targeting software and strict protocols. We wanted to study
the use of 1.5-Tesla mpMRI in active surveillance in the ‘real-
life’ setting.
Prostate-specific antigen dynamics have had mixed
associations with prostate cancer-specific mortality in men
with initial conservative management [19], but there is little
[20] to no research to date on the use of PSA dynamics in
helping to ‘select’ men on active surveillance for further
investigation.
We hypothesize that protocol biopsies can be safely replaced
by selective biopsy and a monitoring programme of repeat
MRI scans, PSA testing and DRE.
The aim of this study was to determine outcomes for men in
a 1.5-Tesla mpMRI-based active surveillance programme, and
to determine if PSA dynamics could predict subsequent
progression in men who remained on active surveillance after
an initial confirmatory biopsy.
Methods
Study Design and Patients
We conducted an analysis of a prospectively collected
observational clinical database.
All patients were diagnosed with Gleason 3 + 3 prostate
cancer (2010–2015) by 10-core systematic TRUS biopsy,
performed because of an elevated PSA level. All patients had
PSA <15 ng/mL and ≤cT2a disease. Patients underwent DRE
in clinic annually and 3-monthly PSA tests, with data
recorded at each visit in our database.
All patients at our institution were included if they
underwent mpMRI after TRUS diagnosis of Gleason 3 + 3
prostate cancer and were on active surveillance. We did not
have a protocol regarding timing of the first mpMRI scan.
This varied based on the patient’s risk (number of positive
cores, PSA level, DRE findings), patient preference and
waiting lists. All patients were offered a confirmatory biopsy
after their first MRI scan, regardless of MRI findings. If
patients remained on active surveillance after a confirmatory
biopsy the MRI was repeated after 2 years. MRI was repeated
sooner if there was a rising PSA, concerning findings on DRE
or high-risk features such as more than two positive cores, or
a relatively high PSA level for a given prostate volume.
However, we did not use set PSA density or kinetic cut-offs.
We did not have a routine re-biopsy schedule after the
confirmatory biopsy at 1 year.
PSA Dynamics
We hypothesized that PSA dynamics could be useful in
guiding further investigation when assessed after the first
MRI scan. Therefore, we chose a period of PSA testing from
up to 12 months before the first MRI scan until up to
18 months after it to calculate PSA dynamics. Equations used
for PSA dynamics were: PSA doubling time (least squares
linear regression of the log2 of at least five PSA values
expressed in years) and PSA velocity (last log2 PSA of series
divided by the series PSA doubling time). PSA dynamics were
assessed for association with progression to radical therapy in
patients who remained on active surveillance after first MRI
(with or without confirmatory biopsy).
Magnetic Resonance Imaging
The MRI was performed on 1.5-Tesla Siemens systems at five
different hospitals. All MRI scans included dynamic contrast
enhancement (8-s temporal resolution), anatomical and
functional diffusion-weighted imaging (B-values: 50, 600 and
1200) with pelvic phased array (no rectal coils used). Primary
MRI reports were by mixed specialist and non-specialist
radiologist. However, all scans were reviewed in a
multidisciplinary team with the presence of expert uro
radiologists. MRI results were scored on a three-point scale:
‘no lesion’; ‘moderate-risk lesion’; or ‘high-risk lesion’.
Moderate-risk lesion was defined as a visible abnormality of
uncertain malignant potential. High-risk lesion was defined as
a visible abnormality that was probably malignant.
Repeat MRI scans were all compared to initial imaging by the
reporting radiologist. These were then coded by the study
investigators as (i) ‘no change/better’ or (ii) ‘worse’. ‘Worse’
was defined as any one of the following: (i) new lesion
identified; (ii) increase in size of previous lesion; (iii) a
moderate-risk lesion now a high-risk lesion; (iv) new or
increased diffusion restriction; (v) new or increased dynamic
contrast enhancement; (vi) new evidence of extraprostatic
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extension. ‘Better’ was defined as at least a one-point
reduction in MRI risk group.
Biopsies
Confirmatory Biopsy
Confirmatory biopsy was offered to all men regardless of MRI
findings. This was the first biopsy after diagnosis, following
the first MRI scan. If there was a visible lesion on MRI, the
confirmatory biopsy was a targeted biopsy along with
systematic sampling. Targeted TRUS biopsy involved 2–4
cores targeted to the lesion, plus systematic sampling up to a
total of 10 cores. Transperineal targeted biopsy was only
performed if an anterior lesion was seen and involved a
minimum of four cores, targeted to the lesion, plus saturation
biopsy of the whole gland (between 24 and 42 cores total).
Selective Repeat Biopsy
Following the confirmatory biopsy no further biopsies were
protocoled. Selective repeat biopsy was considered on a case-
by-case basis with no set criteria. Decision-making was based
on PSA monitoring, annual DRE, serial MRI findings and
patient preference. Selective repeat biopsy was TRUS, unless
an anterior lesion was seen on MRI or suspected (e.g. MRI-
negative patients with rising PSA level and low-volume
disease on TRUS biopsy) in which case transperineal biopsy
was performed.
Follow-up
Outcomes were assessed by review of electronic patient notes.
The outcomes assessed were as follows: (i) rate of progression
to radical therapy at confirmatory biopsy; (ii) rate of
progression to radical therapy in patients who remained on
active surveillance after confirmatory biopsy; and (iii) the
overall rate of progression to radical therapy. Radical therapy
was defined as curative intent brachytherapy, external beam
radiotherapy or radical prostatectomy. Patients who died
from other causes or were converted to watchful waiting
(PSA monitoring only, and consideration of hormone therapy
if applicable) were included in the ‘non-progression’ category.
These patients avoided radical therapy and did not come to
harm from prostate cancer. Patients were converted to
watchful waiting when it was agreed between patient and
clinician that further invasive investigation was no longer of
benefit.
Statistical Analysis
Continuous variables are recorded as mean (95% CI;
normally distributed) or median (25th, 75th; skewed or
kurtotic) and compared using Student’s t-test or the Mann–
Whitney U-test, respectively. Categorical variables are
displayed as number and percentage, and compared using the
chi-squared test. Survival analysis was performed by Kaplan–
Meier plot and groups compared using Cox regression.
Significance was accepted at P < 0.05. Statistics were analysed
using SPSS (SPSS Inc., Chicago, IL, USA) v.21. PSA dynamics
were calculated using the ‘LINEST’ least squares regression
function in Microsoft Excel v1804.
Ethics
This project was an audit and was exempt from ethical
review at our institution.
Results
A total of 401 patients started active surveillance for Gleason
3 + 3 prostate cancer during the period, of whom 211
underwent mpMRI after diagnosis and were included
(Table 1). The first mpMRI scan was at a median of 12.1
(7.3–27.5) months after diagnostic TRUS biopsy. Of the 211
patients, 150 (71.2%) underwent a confirmatory biopsy after
the first MRI (Table 2); 125/211 patients (59.2%) had a lesion
on MRI that was considered targetable, 97 were thought to be
at high risk based on MRI, 28 were thought to be at
moderate risk, and 86 had no visible lesion (Table 2, Fig. 1).
Three patients underwent radical therapy based on first MRI
findings alone without confirmatory biopsy. Fifty-eight
patients elected not to have a confirmatory biopsy and to
continue PSA monitoring with a view to repeating MRI
(Fig. 1). Seven patients were taking 5-a-reductase inhibitors
(PSA values doubled for reporting) at the time of their first
MRI, three with visible lesions and four with no visible lesion.
Overall Progression Rates
With a median of 4.2 (3.4–5.1) years of follow-up, 58/211
patients (27.5%) had progressed to need radical therapy.
Patients with visible lesions on first MRI had significantly
higher rates of progression to radical therapy (Table 1,
Figs 1A and 2) than patients with no visible lesion on first
MRI (Fig. 1B; final progression rate: visible lesion on first
MRI: 47/125 (37.6%) vs no visible lesion on first MRI: 11/86
(12.8%), odds ratio 4.1 (95% CI 2.0–8.5); P < 0.001).
Compared to no visible lesion on first MRI, progression-free
survival was significantly worse in patients with high-risk
visible lesions (hazard ratio 3.5 [95% CI 1.8–6.9]; P < 0.001)
and trended to worse with moderate-risk lesions (hazard ratio
1.99 [95% CI 0.77–5.14]; P = 0.15 [Fig. 2]).
Reasons for Radical Therapy
Five patients elected to receive radical therapy based on
increased volume Gleason 3 + 3 disease on confirmatory or
selective repeat biopsy, usually accompanied by a rising PSA
level. Two patients with Gleason 3 + 3 cancer after targeted
© 2018 The Authors
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confirmatory biopsy of a visible lesion at first MRI
subsequently had a rising PSA level and elected to undergo
radical therapy without further investigation. In all others
(51/58), progression to radical therapy was prompted by
either upgrading on biopsy, T3 on MRI or progressive high-
risk lesion on MRI. All patients who were converted to
watchful waiting were converted before PSA progression.
Gleason Upgrading on Confirmatory Biopsies after
First MRI
The rate of Gleason upgrading was significantly greater in
patients with a targetable abnormality on first MRI (22/94
[23.4%] vs 1/56 [1.8%]; odds ratio 16.8 [95% CI 2.20–128.54];
P = 0.007 [Table 2]). Patients with ‘high-risk’ and ‘moderate-
risk’ lesions had similar rates of upgrading on confirmatory
biopsy (Table 2). Three patients had upgrading to Gleason 3
+ 4 on confirmatory biopsy of a visible lesion but did not
choose radical therapy when offered, all required radical
therapy after further surveillance.
Management of Those Still on Active Surveillance
after First MRI with or Without Confirmatory Biopsy
In patients who remained on active surveillance after first
mpMRI scan with or without confirmatory biopsy (N = 184),
the rate of subsequent progression to radical therapy in those
with visible lesions was 22/100 (22.0%) and 9/84 (10.7%) in
patients with no visible lesions initially. For high-risk visible
lesions the progression rate was 19/76 (25.0%) vs 3/24
(12.5%) for moderate-risk visible lesions.
After first mpMRI (with or without confirmatory biopsy)
81/89 and 55/75 eligible patients with and without visible
lesions, respectively, had repeat (second) mpMRI (Fig. 1).
The median time between first and second MRI was 29.0
(23.0–34.0) months for patients with no visible lesions and
26.7 (19.5–33.0) months for patients with visible lesions.
Management after Second MRI
In patients who had a second MRI scan, radiological
progression was seen in 33/81 patients (40.7%) with known
visible lesions. In patients with no visible lesions on first MRI
scan 17/55 patients (30.9%) developed lesions on second MRI
scan.
Significant differences in the need for radical therapy at this
stage were seen based on the combined findings of the two
scans (Table 3). Patients with an unchanged (n = 45) or
better (n = 3) visible lesion had the lowest progression rate
(1/48 [2.1%]) vs patients with a new visible lesion (5/17
[29.4%]), or a progressive visible lesion (19/33 [57.6%])
(Table 3). Decision-making regarding the need for selective
Table 1 Baseline characteristics of patients in the study, with and without progression, defined as requirement for radical therapy.
All No progression Progression Odds ratio P
Number of men, n (%) 211 153 (72.5) 58 (27.5) – –
Mean age, year 65.3 (64.5,66.1) 65.1 (64.2, 66.1) 65.6 (64.0, 67.2) – 0.55
Median number of positive cores 1 (1–2.25) 1 (1–2) 2 (1–4) – 0.001
More than two positive cores 50 (23.7) 25 (16.3) 25 (43.1) 3.88 (1.98–7.60) <0.001
Median percentage length cores involved 5 (2.5–10) 5 (2.5–10) 5 (2.5–15) – 0.05
Mean PSA 6.8 (6.2, 7.3) 6.9 (6.1, 7.6) 6.5 (5.7, 7.2) – 0.89
Median PSA density 0.11 (0.08–0.17) 0.10 (0.08–0.16) 0.12 (0.10, 0.18) – 0.03
Visible lesion on first MRI, n (%) 125 (59.2) 78 (51.0) 47 (81.0) 4.1 (2.0–8.5) <0.001
Had confirmatory biopsy, n (%) 151 (71.6) 105 (68.6) 46 (79.3) 1.8 (0.9–3.6) 0.13
Values are mean (95% CI) or (median 25th, 75th) unless otherwise specified. Reasons for radical therapy are described in the text.
Table 2 Confirmatory biopsy findings after first MRI.
All No visible lesion High-risk lesion Moderate-risk lesion
Number of men, n (%) 211 86 (40.8) 97 (46.0) 28 (13.3)
TRUS, n 139 54 68 17
Transperineal, n 12 2 7 3
Total had confirmatory biopsy, n (%) 150 (71.1) 56 (65.1) 74 (76.3) 20 (71.4)
Any upgrade, n/N (%) 23/150 (15.3) 1/56 (1.8) 17/74 (23.0) 5/20 (25.0)
Benign, n 39 25 10 4
3 + 3 89 30 48 11
3 + 4 21 1 15 5
4 + 3 2 0 2 0
>4 + 3 0 0 0 0
Volume increase on biopsy prompting radical therapy 4 1 3 0
4
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targeted biopsy: Rx
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targeted biopsy: Rx
Straight to radical
therapy based on MRI
Radical therapy based
on MRI
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watchful waiting
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radical therapy
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Remain on active
surveillance
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4
8
5
1
1
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MRI no change or
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MRI no change or
better 38/55 (69.1)
8/18 (52.9)
MRI progression
33/81 (40.7)
MRI progression
17/55 (30.9)
10/18 (55.6)
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40/63 (61.5)
23/63 (37.0)
3
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0
0
0
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1
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63
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(12.8)
2
3
3
3
1
7
25
10
1
1
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12/17 (70.6)
5/17 (29.4)
1
5 10
26/38 (68.4)
12/38 (33.3)
30
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No biopsy
No biopsy
1
1
3
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First MRI
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protocol
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biopsy diagnosis
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biopsy diagnosis
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1-2
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years years
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  all stages)
Summary outcome (at
  all stages)
Following second MRI
Following second MRI
Second MRI N = 81
Second MRI N = 55
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1-2
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converted to watchful
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Volume increase on
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Volume increase on
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Gleason upgrade : radical
therapy
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PSA progressed before
further MRI–had
radical therapy
Outcome following
confimatory biopsy
Outcome following
confimatory biopsy
Confirmatory biopsy
Confirmatory biopsy
Selective systematic 
biopsy : no upgrade - AS
Fig. 1 The flow of patients through the study. (A) Patients with visible lesions on MRI 1. (B) Patients with no visible lesion on MRI 1. All 28 patients with
visible lesions who did not have an initial confirmatory biopsy had small lesions with stable PSA and elected for PSA monitoring and repeat MRI before
undergoing a biopsy. AS, active surveillance; Rx, treatment.
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repeat biopsy is described in Table 3. Time between second
MRI and selective repeat biopsy ranged from 0.2 to 9 months
(median 2.4 months) for patients with worsening MRI results
and from 0.5 to 17 months (median 2.05 months) for
patients with no change on MRI.
PSA Dynamics for Prediction of Progression in
Patients who Remained on Active Surveillance after
Confirmatory Biopsy
When calculated 12–18 months after the first MRI using at
least five PSA values, PSA velocity was significantly
associated with subsequent requirement for radical therapy
in patients with no visible lesions, and PSA doubling time
was significant in patients with visible lesions (Table 4). The
area under the receiver-operating curve (AUC) for PSA
velocity for prediction of progression in MRI-negative
patients was 0.85 (95% CI 0.75–0.94); for doubling time in
MRI-positive patients, the AUC was 0.65 (95% CI 0.52–
0.78). In patients with no visible lesions on first MRI, a cut-
off of 0.5 ng/mL/year in PSA velocity had a sensitivity of
89% (8/9 progressions identified) and a specificity of 75% for
progression to radical therapy (Fig. 3). Having more than
two positive biopsy cores at baseline was also significantly
associated with subsequent progression in patients with
visible lesions (Table 4).
Progression free survival accoring to lesion status on MRI 1
Lesion status MRI 1
Not visible
High risk visible
Moderate risk visible
Not visible-censored
High risk visible-
censored
Mod risk visible-
censored
1.0
0.8
0.6
Pr
og
re
ss
io
n-
fr
ee
 su
rv
iv
al
0.4
0.2
0.0
0 1 2 3
Time (years)
4 5 6
Fig. 2 Kaplan–Meier survival analysis categorized by no visible lesion (n =
86), moderate-risk visible lesion (n = 28) and high-risk visible lesion (n =
97). Graph truncated at 6 years. Cox regression hazard ratio high-risk vs
no lesion: hazard ratio 3.5 (1.8–6.9), P < 0.001; moderate-risk vs no lesion:
hazard ratio 1.99 (0.77–5.14), P = 0.15.
Table 3 Requirement for radical therapy after second MRI, grouped by comparative findings between first MRI and second MRI.
MRI 1 No visible lesion Visible lesion
MRI 2 No visible lesion Developed new lesion Stable/better lesion MRI Progression*
N 38 17 48† 33
Required radical therapy 4 (10.5) 5 (29.4) 1 (2.1) 19 (57.6)
Straight to radical
therapy no biopsy
0 2 0 15
Selective repeat biopsy* 11 (3 upgraded, 8 not) 11 (3 upgraded, 9 not) 14 (1 upgraded, 13 not) 12 (4 upgraded, 8 not)
Reasons for selective
repeat biopsy
New/worsening lesion 0 11/11 0 12/12
DRE changes 3 – 3 –
Rising PSA 6 (3 upgraded – 1 on TP biopsy done as
PSA felt out of keeping with TRUS
findings)
– 6 –
Persisting high-risk lesion:
concern not adequately
sampled first time
– – 3 (1 upgraded) –
Patient request 2 – 2 –
Reasons for no biopsy N = 23: no MRI lesion, no other indication
to repeat. Continue PSA and MRI
monitoring.
N = 2: small lesion, low PSA:
repeat MRI in 1 year
N = 1: patient refused, against
medical advice
N = 1: awaiting biopsy
N = 34: Stable DRE
and PSA, no MRI
change, repeat
MRI in 1 year
N = 2: Awaiting biopsy
N = 3: Small lesions,
low PSA, already been
targeted with reassuring
findings – await a repeat
MRI in 1 year with close
PSA monitoring
N = 1: Died,
non-prostate cancer
Decision-making in selective repeat biopsy. *Definitions of MRI progression can be found in the methods section. Reasons for radical therapy are described in the text. †Only three
men had lesions that were considered ‘better’. All had high-risk visible lesions initially.
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Patients Who Did Not Have a Confirmatory Biopsy
after First MRI
There was no difference in the rate of progression overall at
any stage for patients with no visible MRI lesion who had a
confirmatory biopsy (7/56 [12.5%]) vs those who did not (4/
30 [13.3%]; P = 0.87). In patients with visible lesions, of those
not requiring treatment based on first MRI, 28/122 (22.9%)
elected not to have an initial targeted biopsy because of small
or moderate-risk lesions with low/stable PSA, in favour of
MRI and PSA follow-up. Four of these 28 (14.3%) progressed
to radical therapy at last follow-up, three had progressive
lesions on second MRI and one had a rising PSA level and
elected to undergo treatment without further investigation
(Fig. 1A).
Were Patients Treated Within the ‘Window of
Curability’ if they Remained on Active Surveillance
after Stage 1?
In patients who remained on active surveillance after first
MRI, (with or without confirmatory biopsy), and went on
to later require radical therapy, 25/31 had a PSA level < 10
ng/mL at the time of radical therapy and six had a PSA
level >10 ng/mL. Their diagnosis and pre-radical therapy
PSA values were as follows: 7.9–14.1, 11.5–14.3, 14.7–11.1
ng/mL (160 mL prostate volume), 6.7–13.3, 7.2–16.4 and
3.5–10.8 ng/mL. Three of the 31 patients had possible early
T3 disease on a second MRI and underwent radiotherapy
without further biopsy, all had visible lesions initially.
Discussion
The aim of the present study was to describe outcomes for
men on active surveillance using mpMRI-, PSA- and DRE-
based monitoring with selective re-biopsy. We showed that
routinely performing confirmatory biopsy in men with no
visible lesion on MRI has a low diagnostic yield. We then
showed that sequential MRI scans with PSA monitoring can
identify disease progression regardless of lesion status on first
scan. Finally, we showed that PSA dynamics are associated
with subsequent progression in men with negative MRI
results.
This is the first study, to our knowledge, reporting MRI
progression rates in patients with known low-risk prostate
cancer, without protocoled biopsy beyond the first year and
with 4 years of follow-up. It is also the first study, to our
knowledge, that assessed PSA dynamics in patients who
remained on active surveillance after the first MRI scan/
confirmatory biopsy.
Only one out of 56 patients with no visible lesion on first
MRI had upgrading at routine confirmatory biopsy. This
patient had organ-confined low-volume Gleason 3 + 4 cancer
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at radical prostatectomy. In patients with no visible lesions,
repeat MRI identified new lesions in 32%, although only 4/17
needed radical therapy at that stage. Even when a second
MRI was still negative, PSA dynamics and DRE selected 11/
38 of these patients for repeat systematic biopsy. Of these
selective repeat biopsies in MRI-negative patients, 36% had
upgrading; thus, when the first MRI is negative, the
diagnostic yield of repeat MRI with delayed selective biopsy is
significantly higher than performing a routine confirmatory
biopsy in all.
The practice of routine systematic confirmatory biopsy for
men on active surveillance was based on evidence from the
pre-MRI era that up to 35% of men would be upgraded at
repeat biopsy [3]. This is no longer the case when MRI risk
stratification is taken into account. Other studies have shown
that ~10% of men on active surveillance with no visible MRI
lesion will be found to have upgrading if routine
confirmatory biopsies are performed [8,21,22]. In the present
study, only 1.8% of patients with negative MRI were found to
have upgrading on confirmatory biopsy. Our patient
populations are similar to previous studies in terms of clinical
risk predictors [8,21,22]; however, in the present study,
35% of patients with no visible lesion elected not to have a
routine confirmatory biopsy and to await repeat MRI and
PSA monitoring.
Regardless of the confirmatory biopsy findings in MRI-
negative patients, during 4 years of follow-up, MRI and PSA
monitoring with selective re-biopsy identified 10% requiring
radical therapy. This is similar to the rate of radical therapy
required in MRI-negative patients in other studies [5].
Furthermore, after the confirmatory biopsy, only 23 of the
remaining 84 MRI-negative patients needed to be subjected to
a repeat biopsy to identify these 10% with upgrading. Finally,
the rate of progression over the course of 4 years was the
same in patients who had a confirmatory biopsy as in those
who did not. Thus, we believe the routine, protocoled
confirmatory biopsy, could have been safely omitted in
patients with negative MRI scans, in favour of further
monitoring with selective re-biopsy.
We accept that since most of our confirmatory biopsies were
systematic TRUS biopsies it is possible more upgrading may
have been identified in MRI-negative patients had
transperineal template biopsies been undertaken. There is
some evidence to suggest this may be the case [23]; however,
there is no evidence that this is beneficial for long-term
outcomes. We would not recommend more aggressive
investigation of MRI-negative patients with very low-risk
prostate cancer at baseline, given the low rates of progression
and safe identification of progression with MRI/PSA
monitoring shown in the present study.
In patients with reassuring biopsy of a visible lesion who
remained on active surveillance, 41% had some form of MRI
progression. Half of these underwent radical therapy (either
based on repeat MRI findings alone or following a repeat
targeted biopsy). Patients with high-risk lesions account for
the majority of these. In contrast to patients with high-risk
lesions on first MRI, patients with moderate-risk lesions who
had reassuring confirmatory biopsies approached the rate of
progression in patients with no visible lesions (12.5% vs
10%). The rate of upgrading at targeted confirmatory biopsy
of visible lesions in the present study was lower than that
reported elsewhere [5] (23% vs 35%). However, with 4 years’
follow-up, 37% of patients with visible lesions on first MRI
required radical therapy. All but one patient with a visible
lesion and subsequent need for radical therapy demonstrated
clear MRI progression. This suggests that true cancer
progression, rather than inadequate targeting may explain
progression in these patients. MRI surveillance with or
without selective repeat biopsy was able to identify all
patients who progressed before any significant PSA
progression. Of 33 patients with MRI progression, 15 were
able to progress straight to radical therapy without further
biopsy, again reducing the number of biopsies required.
PSA velocity was strongly associated with progression in
patients who remained on active surveillance with negative
MRI. In patients with negative MRI, PSA velocity should be
given weight when selecting for earlier repeat MRI  biopsy,
accepting there is overlap in values between patients with and
without progression. PSA dynamics showed less clear
PSA velocity
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Fig. 3 PSA velocity in patients who remained on active surveillance after
the first MRI scan (with or without confirmatory biopsy). Progression is
defined as requiring radical therapy. PSA velocity values are truncated
excluding outliers to allow visualization of the mid-range values. Red box
represents a cut-off 0.5 ng/mL/year where these patients could be
selected for earlier repeat investigation.
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association with progression in patients with visible lesions
and are unlikely to be clinically useful in this circumstance
(Fig. 3). We accept that PSA dynamics may not be predictive
of long-term prostate cancer-specific mortality in men on
active surveillance [19,24]. We believe that PSA velocity can
be used specifically to select men on active surveillance with
negative MRI for further investigation and is complementary
to a holistic clinical assessment in this circumstance.
A limitation of the present study is that our population
represents a ‘very-low-risk’ active surveillance population.
This is because we only included patients who had mpMRI
after starting active surveillance. Prior to 2014 many patients
had simple MRI scans for local staging and thus could not be
included. We also did not have data on those who progressed
to radical therapy prior to the first MRI scan. This is in fact
true of most similar studies in the field [21,22], but must be
borne in mind when interpreting these studies and ours. It
does not detract from results related to follow-up of patients
who remained on active surveillance.
Our clinical service did not use a standardized MRI risk
categorization or reporting template (such as Prostate
Imaging Reporting and Data System [PI-RADS] [25] or the
PRECISE recommendations [26]). MRI risk was assessed at
multidisciplinary team review. Visible abnormalities were
reported as likely to be malignant or equivocal for
malignancy. It is possible that five-point MRI risk
categorization may have better risk-stratified patients in a
larger cohort [11]. Kaplan–Meier analysis showed well-
calibrated risk of progression based on the three MRI risk
levels that we assigned. We believe there would have been
minimal additional prognostic discrimination from a five-
point scale in the present population.
This was a prospective observational study of our normal
clinical practice; therefore, we did not record radiological/
pathological correlation at radical prostatectomy. We also did
not formally double-report MRI to allow concordance
assessment. Validation of the accuracy of MRI reporting is
provided by the upgrading at targeted biopsy and radical
therapy progression rates in the three lesion risk groups we
assigned (Table 2, Fig. 2). We believe this reflects ‘real-life’
active surveillance and MRI reporting outside of the trial
setting. Such data are useful and complementary to controlled
trials.
In summary, routine confirmatory biopsy in patients with
MRI-negative, TRUS Gleason 3 + 3 cancer on active
surveillance has low diagnostic yield. Subsequent follow-up of
MRI-negative patients with PSA/MRI/DRE without further
protocol biopsies demonstrated low progression rates and
timely identification of those in need of radical therapy.
Patients with malignant visible lesions are a high-risk group
even after reassuring targeted biopsy. PSA dynamics have
limited value in patients with high-risk MRI lesions. We
suggest that patients with high-risk lesions on first MRI who
remain on active surveillance after a targeted biopsy should
be offered an early repeat MRI (at 1 year or sooner)
regardless of PSA dynamics. Patients with negative MRI, or
reassuring biopsy of low-/moderate-risk lesions, can defer
repeat MRI for 2 years, unless the PSA is rising or DRE
changes.
In conclusion, men with low-risk Gleason 3 + 3 prostate
cancer on active surveillance can forgo protocol biopsies in
favour of MRI and PSA monitoring with selective repeat
biopsy.
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